Dyskinesia

News Dyskinesia

• One ion channel, many diseases

  A dysfunction of a certain Calcium channel, the so called P/Q-type channel, in neurons of the cerebellum is sufficient to cause different motor diseases as well as a special type of epilepsy. This is reported by the research team of Dr. Melanie Mark and Prof. Dr. Stefan Herlitze from the Ruhr-Univer more

• Parkinson treatment shows positive results in clinical testing

  Researchers from the University of Florida and 14 additional medical centers reported results in The Lancet Neurology journal indicating that deep brain stimulation — also known as DBS — is effective at improving motor symptoms and quality of life in patients with advanced Parkinson’s disease. The s more

• Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

  Biotie Therapies Corp. announced  the start of a Phase 2b trial evaluating SYN115 in Parkinson's Disease (PD). Results from the study are expected in the first half of 2013.SYN115 is an orally bioavailable potent and selective adenosine A2a receptor antagonist. Adenosine A2a inhibition has been show more

Publications Dyskinesia

• Multilocus genetic models of handedness closely resemble single‐locus models in explaining family data and are compatible with genome‐wide association studies

  Right‐ and left‐handedness run in families, show greater concordance in monozygotic than dizygotic twins, and are well described by single‐locus Mendelian models. Here we summarize a large genome‐wide association study (GWAS) that finds no significant associations with handedness and is consistent more

• Association of the dopamine β‐hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia

  Objective Overactivity of dopaminergic neurotransmission is a putative mechanism of tardive dyskinesia (TD). Dopamine beta‐hydroxylase (DBH) is a key enzyme in the conversion of dopamine to norepinephrine, and plasma DBH activity is altered in TD patients. This study examined whether the functio more

• Haloperidol‐induced striatal Nur77 expression in a non‐human primate model of tardive dyskinesia

  Abstract Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication arising in patients chronically exposed to antipsychotic drugs. As several modern (so‐called atypical) antipsychotic drugs are common offenders, combined with the widening clinical indications for presc more

Market studies Dyskinesia

• Dyskinesia – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Dyskinesia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dyskinesia, complete with latest updates, and special features on late-stage and discont more

• Tardive Dyskinesia – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Tardive Dyskinesia - Pipeline Review, H2 2012', provides an overview of the Tardive Dyskinesia therapeutic pipeline. This report provides information on the therapeutic development for Tardive Dyskinesia, complete with latest updates, and special features on more

• Tardive Dyskinesia – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Tardive Dyskinesia - Pipeline Review, H1 2012', provides an overview of the Tardive Dyskinesia therapeutic pipeline. This report provides information on the therapeutic development for Tardive Dyskinesia, complete with latest updates, and special features on l more

Websites Dyskinesia